



Drug-related infectious diseases meeting – Agenda - Lisbon time (GMT+1)

DRID coordination group: Thomas Seyler, Dagmar Hedrich, Isabelle Giraudon, Bruno Guarita, Marisa Gomes.

Contact person: thomas.seyler@emcdda.europa.eu

Conferencing System: Zoom®

DAY 1: 22 October 2020

8.30-8.45: Registration and guidelines for the online platform

8.45-8.55: Introduction and updates from EMCDDA, Thomas Seyler

Session 1. COVID-19 and drug use

8.55-9.20: **COVID-19 risk among drug users** (Chair: AN, co-chair: TS)

- Results from a SARS-Cov2 sero-prevalence study among drug users in Czechia, Barbara Janikova, Czechia
- COVID19 infections among people in prison, preliminary data from Villeneuve les Maguelone, France, Fadi Meroueh, France
- COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States, published by Wang *et al.*, TS

9.20-10.10: **Impact of COVID-19 on harm reduction services**

- COVID-19 impact on harm reduction programs (testing and counselling) in low threshold drug services in Germany, Amrei Krings, Germany
- Prevention measures to prevent HIV among PWID during Israel's COVID Response: Preliminary Findings, Daniel Chemtob, Israel
- Disruption and adaptation of harm-reduction services during the pandemic, Eberhard Schatz, Rafaela Rigoni, Correlation
- Assessing the impact of COVID-19 on testing for multiple infectious diseases in Europe, Annemarie Rinder Stengaard, EuroTEST
- Report on vulnerable populations and COVID-19, John Kinsman, ECDC

Session 2. Sustainable Development Goals (HIV and viral hepatitis)

10.20-10.50: **Overview** (Chair: IG, co-chair: TS)

- HIV and Hepatitis monitoring overview in the EU, Teymur Noori, ECDC
- Update on non-EU countries, Nicole Seguy, WHO
- Barometer updates and HCV initiative, Thomas Seyler, EMCDDA

10.50-11.15: **Prevention (focus on HBV)**

- HBV trends and HBV vaccination among PWID in Italy, Barbara Suligoj, Italy
- HBV in EU prisons: opportunities and challenges for action, Erika Duffell, ECDC

11.15-11.50: **Continuum of care (focus on HCV and HIV)**

- Integrated treatment of hepatitis C virus infection among people who inject drugs: a randomised controlled trial (INTRO-HCV) in Norway, Lars Fadnes, Norway



- Barriers to HCV treatment among PWID before and during the DAA era: The ANRS FANTASIO project, Fabienne Marcellin, France

Session 3. Documenting evidence-based interventions

12.00-12.30 (chair: KS, co-chair: ABE)

- ECDC and EMCDDA review and updating of Guidance - Prevention and control of infectious diseases among people who inject drugs, Anne Bergenström, EMCDDA and Otilia Mardh ECDC
- HCV testing initiative, Klaudia Palczak, EMCDDA

DAY 2: 23 October 2020

Session 4. Drug-related infectious diseases outbreaks

08.30-9.15 (chair: TS, co-chair: LM)

- Round table on lessons learned from previous HIV outbreaks (detection, risk factors, interventions)
 - o Lithuania (Lina Jurgelaitiene, Viktorija Stifanoviciute)
 - o Germany (Ruth Zimmerman)
 - o Luxembourg (Carole Devaux)
 - o Glasgow (Andy McAuley)
- HCV outbreak in a prison in Australia, Darren Russel, Australia

Session 5. Monitoring tools for SDG among PWID

9.15-10.30 (chair: KS, co-chair: BG)

- Round table on city-level RDS studies among PWID:
 - o Lithuania (Marija Jakubauskienė)
 - o Belgium (Luk Van Baelen)
 - o Romania (Viviana Manolache)
 - o Luxembourg (Carole Devaux)
 - o Hungary (Anna Horváth-Tarján)
- Assessing HIV, hepatitis B and C, and Syphilis among people who inject drugs in Germany – Pilot study for a continuous national monitoring system, Gyde Steffen, Germany
- DRID data collection updates, Bruno Guarita, EMCDDA

Conclusions

10.30 – 11.00

- Next steps, round table
- AOB